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H I G H L I G H T S
• Children with heterozygous familial hypercholesterolaemia (FH) should be managed by paediatric health professionals with expertise in FH.• Statin to be considered by the age of 10 years and use age appropriate target LDL-C level in children with FH.• Dietary and life style advice should begin in early childhood.• From the age of 14 years, consider joint review with adult lipidologist in transition clinic with transfer to adult lipid clinic at 16 to 18 years.
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A B S T R A C T
This consensus statement on the management of children and young people with heterozygous familial hy-
percholesterolaemia (FH) addresses management of paediatric FH in the UK, identified by cascade testing when
a parent is diagnosed with FH and for those diagnosed following incidental lipid tests. Lifestyle and dietary
advice appropriate for children with FH; suggested low density lipoprotein cholesterol (LDL-C) targets and the
most appropriate lipid-lowering therapies to achieve these are discussed in this statement of care. Based on the
population prevalence of FH as ~1/250 and the UK paediatric population, there are approximately 50,000 FH
children under 18 years. Currently only about 550 of these children and young people have been identified and
are under paediatric care.
1. Aim
This is a consensus statement by HEART UK on a strategy with age-
appropriate guidance for managing children and young people with
heterozygous FH in the UK. Martin and colleagues have recently re-
viewed knowledge about FH in children [1]. The existing NICE CG71
guideline does not address in detail the management of children with
FH. We aim to do this here and suggest practical LDL-Cholesterol target
concentrations. We have not included formal evidence grading of the
recommendations since this is a position statement of UK paediatric FH
expert opinion.
2. Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant in-
herited metabolic disorder characterised by elevated low-density lipo-
protein cholesterol (LDL-C) concentrations from birth with premature
coronary heart disease (CHD) occurring in approximately half of men
by age 50 and one third of women by age 60 [2]. Lifetime exposure to
LDL-C correlates with increased risk of cardiovascular disease [3].
Prospective studies and randomized trials are consistent in showing
that the relationship between LDL-C cholesterol and CHD is causal
[4,5], with a direct proportional relationship between LDL-C and risk.
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In addition, using a 9-SNP LDL-C “genetic score” Ference et al. [6] have
demonstrated that prolonged exposure to lower LDL-C beginning early
in life is associated with a substantially greater reduction in the risk of
CHD than the current practice of lowering LDL-C beginning later in
adulthood.
In more than 90% of the UK FH patients where a mutation is found the
underlying genetic cause is within the LDLR gene, which encodes the low-
density lipoprotein receptor (LDL-R). In around 5% of UK patients the
genetic cause is a single mutation in apolipoprotein B (APOB), and in about
2% a single mutation in proprotein convertase subtilisin/kexin type 9
(PCSK9) [7]; a single deletion variant in APOE (p.Leu167del) is also re-
ported to cause the FH phenotype in a few families [8]. In patients where
no causative mutation can be found a polygenic cause of their hyperlipi-
daemia is most likely [9]. Finding the underlying monogenic cause of FH in
an index case allows cost effective DNA-based “cascade testing” in their
relatives, an approach recommended in most FH guidelines, that will in-
crease the number of FH children identified. A HEART UK consensus
statement on Homozygous FH (including children) was published in 2016
[10] and Homozygous FH will not be further discussed here.
No randomised, placebo-controlled trials of cholesterol reduction to
reduce CHD events have been carried out in children with FH because,
as for adults, their high risk makes a placebo arm unethical. Since a
child is likely to develop CHD in their 5th-6th decade, it is also im-
practical to fund an RCT of the benefit of statin therapy because of the
time needed to observe such a benefit. Mendelian randomization stu-
dies (natural randomized trials) indicate that individuals with genetic
polymorphisms that lower LDL cholesterol from birth have an approx-
imate 90% lower risk of CHD in adult life compared with individuals
without such polymorphisms and higher LDL cholesterol from birth. It
follows that children with FH have a markedly elevated risk of future
CHD because of their life-long elevated LDL-C and that reducing their
LDL-C will reduce their future risk of CHD.
Although statin use in the general population has been associated
with an increased risk of developing type 2 diabetes (T2D), this risk
seems not to be high in patients with FH. Many studies have reported
that the prevalence of T2D is low in adults with FH, and in a study of
over 63,000 subjects from Holland [11], even in treated adults with FH
the prevalence of T2D was significantly lower than in their unaffected
relatives (1.75% vs 2.93%). Also, the benefits of statin treatment in FH
for preventing CHD outweighs any modest potential excess risk of Type
2 diabetes [12]. However it is important to mitigate this risk with the
dietary and lifestyle advice for the prevention of T2D/metabolic syn-
drome, as is used in the general population. A study in 2014 reported on
a 10-year follow-up of 194 statin-treated children (mean age at baseline
13 years) and identified one new case of Type 2 Diabetes with a similar
incidence in their 83 non-FH siblings [13].
The psychological effects of any screening or testing process include
how a person thinks (risk perception and understanding of diagnosis), feels
(levels of anxiety, depression, reassurance) and behaves (coming for repeat
screening, taking medication, changing lifestyle). It is possible that relatives
may become anxious, or angry, when they receive news that they are at risk
of having an inherited disorder like FH. However, studies suggest that re-
latives usually believe that genetic information is beneficial [14]. There are
fewer data on the additional psychological impact of DNA testing (over and
above cholesterol testing) in FH patients, and also few data examining this
specific issue in children. An early study of 152 boys and girls aged 7–16
years from Norway [15] concluded that the prevalence of psychosocial
dysfunction was no greater in children treated for FH than in the normal
population. In summary, we are not aware of any short or medium term
studies that have reported any evidence of harm in children identified as
having FH through cascade testing programmes.
Children with heterozygous FH seldom present with identifiable
clinical features. However, using ultrasound to measure carotid intima
media thickness (CIMT), it has been shown that there is progressive
development of atherosclerosis through childhood [16]. CIMT is widely
accepted as marker of the presence of atherosclerosis in the arterial tree
in adults. Individuals in the top quintile of CIMT have a higher future
risk of CHD [17] and CIMT in childhood is therefore a useful predictor
of CHD in later life. As a consequence of having roughly twice the
normal LDL-C concentrations from birth children with FH develop
atherosclerosis that is detectable as significantly increased CIMT com-
pared with their non-FH siblings by the age of 8–10 years [18]. The
finding that children with FH have increased carotid intima media
thickening (an early marker of atherosclerosis) compared with their
non-FH siblings supports the view that atherosclerosis starts early in life
and justifies treatment also beginning early in life.
The European guidelines for children with FH recommend that
statin treatment in children with FH should be considered by the age of
8 years and that LDL-C be lowered by 50% in children less than 10 years
and lowered to below 3.5mmol/l in those over 10 years [19]. NICE
CG71 recommends consideration of statins by the age of 10 years but
with no specific LDL-C targets [20].
3. Diagnosis
Children and young people with FH are, based on current service
provision, most likely to be identified through cascade testing in a fa-
mily where a mutation has been identified in an index case, as shown in
Fig. 1 [adapted from reference [19]].
NICE CG71 recommends that children who are at 50% risk of having
FH, because they have an affected parent, should be offered a DNA test
before their 10th birthday, or as soon as possible after that age.
Children can be tested soon after birth if the parents want this. Cascade
testing is currently being carried out in many centres throughout the UK
[21], and since 2015 approximately 250 children aged less than 10
years and 250 young people aged 10–20 years have been identified.
These individuals are being referred to and managed in 60–70 centres
across the UK, at paediatric or specialist lipid clinics across the UK with
paediatric health care professionals.
DNA analysis for the mutation identified in the index patient is
unambiguous and therefore recommended for family cascade testing for
FH. Lipid measurements can be used for relatives of patients with a
clinical diagnosis of FH in whom the mutation is unknown. Though
fasting lipid measurements are ideal, results from a non-fasting sample
have acceptable accuracy to indicate whether a child is affected and
may be more feasible for young children where fasting is difficult. The
total-cholesterol and LDL-C thresholds for a diagnosis of an FH proband
from the general population are too high for use in relatives, given the
greater prior probability of a first-degree relative having FH (50% vs 1/
250). To overcome this, sex-specific total- and LDL-C diagnostic cut-offs
were established by Starr et al. [22] and recommended by NICE CG71
[2008]. These charts (Supplement S1) were derived from measurements
made in mutation positive and negative relatives and assign a post-test
probability of FH (illustrated by red/grey/green banding) in relatives
with a pre-test probability of 50%. The presence of a grey zone further
emphasises the value of an unambiguous diagnosis with a DNA test,
which eliminates the diagnostic uncertainty of the lipid “grey zone”.
4. Statement 1: identification
a. It is recommended that cascade testing of children be undertaken by
age 10 years in families where an FH mutation has been identified,
by testing for the mutation identified in the index case.
b. Children and young people are referred to a professional with ex-
pertise in managing paediatric FH for screening and confirmatory
tests for FH.
c. Full informed parental consent for DNA testing should be obtained
with child assent if appropriate.
d. Mutation analysis, if not already done in the affected parent, should
include the child and parent and be done by comprehensive DNA
sequencing of introns and exons of all known FH-causing gene loci
in an accredited laboratory.
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e. In FH families where the genetic basis is unknown, LDL-C con-
centrations can be used for cascade screening with the cut-offs es-
tablished by Starr et al. [22; Supplement 1].
5. Clinical management of children and young people with FH
The proposed care pathway for FH children identified either by
cascade testing (CT) or following the detection of elevated cholesterol
concentration is presented in Fig. 2.
The first clinic visit after identification should be by a health care
professional with expertise in managing children and young people with
FH. This may be a paediatrician or a paediatric clinical nurse specialist;
we will refer to them as paediatric FH professionals. The paediatric FH
professional should ensure a child friendly setting & refer to the ‘National
service framework for children, young people and maternity services’
(www.dh.gov.uk) [23]. We anticipate that General Practitioners (GPs)
will play a larger role in the management of paediatric FH in the future,
and that paediatric FH professionals will develop shared care arrange-
ments, with clear guidelines on management, follow up and indications
for referral back to secondary care. Cascade screening and the manage-
ment of FH in childhood are relatively new, however, so we believe that
it would be premature for GPs to undertake this at present.
Fig. 1. Identification of childhood heterozygous FH.
Exclude secondary causes of high cholesterol. For children and young people with definite FH, clinical follow up and management is detailed in Figs. 2 and 3.
Fig. 2. Clinic visit pathway for children and young
people with FH.
The first clinic visit after identification should be a
review by a healthcare professional with expertise in
paediatric FH.
Following that, an Individualised Care Plan should be
drawn, detailing timing and setting for further clin-
cial reviews. Follow up should be by a paediatric FH
healthcare professional. A lipid profile should be
taken at age 8 years to assess whether lipid lowering
therapy should be considerd or defered until age 10
years. Following initiation of statin treatment, pa-
tients should be reviewed by a paediatric FH profes-
sional every 6–12 months to monitor side effects and
to assess tolerabilty and efficacy or more frequently
as required. Follow up could be a combination of face
to face and telephone consultations as appropriate.
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An individualised care plan should be formulated at the initial
meeting and shared with the GP and parents. Until 8 years of age, re-
view by a paediatric FH professional every 2 years is usually sufficient
and these may be telephone consultations, though face-to-face follow-
up is suggested if there is a strong family history of early onset CHD and
a LDL-C level ≥5mmol/l. Face-to-face review is recommended for all
children with FH at 8 years of age, with a lipid profile to help decide
whether lipid lowering therapy should be started or defered.
Life-style changes are the first management strategy for all children
and young people with FH. Molvin et al., in 2013 [24] and the NICE
guideline CG71 [20] recommended that children identified with FH and
their families should receive advice on a healthy lifestyle (diet, exercise
and smoking) as shown in Box 1. The emerging epidemic of childhood
obesity seen in the UK, with over 21% of 11–15 year olds having a BMI in
the “obese” range (>95th percentile for age and gender) [25], makes this
lifestyle information particularly important. Data from the UK Paediatric
FH register has shown that the prevalence of obesity is around 50% lower
in patients with recognized FH than in the UK general population [26],
highlighting the direct benefit to the child of early identification.
The decision to start treatment with a statin should be made jointly
with the child and their family; it is based primarily on their age, level
of LDL-C and the family history of early CHD. Other risk factors for
CHD, such as diabetes or renal disease and south Asian ethnicity, should
also be considered. In the presence of a family history of elevated Lp(a),
it would be of potential clinical utility to measure this in the child [1].
However, there is currently no published evidence to support the
routine measurement of Lp(a), nor has it been identified as an added
risk factor in children with HeFH. In the absence of a suitable inter-
vention for elevated Lp(a), in our experience, it adds to parental an-
xiety. Generally, biochemical and inflammatory markers, genetic risk
scores, CIMT measurement and other forms of imaging have not pre-
dicted risk accurately enough to be of clinical utility [1].
Treatment with a statin should be considered from 8 years if there is a
strong family history of early CHD and LDL-C is > 4mmol/l; it is occa-
sionally appropriate to start a statin before 8 years of age. In patients aged
less than 10 years, we suggest aiming for a 30–50% reduction of LDL-C
from baseline values. Clinical review is recommended 3–6 monthly in the
first year after starting a statin and then every 6–12 months to monitor for
possible side effects and to assess the efficacy of treatment.
In children with FH over 10 years of age, a statin should generally
be started if LDL-C is > 3.5mmol/l. This must, however, be agreed
with the child and their parents, who are sometimes reluctant to start a
statin even after 12 years of age. It may be appropriate to defer treat-
ment for longer, particularly if there is no family history of early CHD;
this situation will become commoner if universal screening is in-
troduced (see section 15 below).
The European guidelines for children with FH recommend a 50%
reduction of LDL-C from baseline in the first 12 months of commencing
statins, with a longer-term goal of maintaining LDL-C below 3.5mmol/l
(19). This is still higher than the target concentrations of< 2.5mmol/l
recommended in adults with FH without CHD, and 1.8mmol/l in those
with CHD [27,28].
Box 1
Confirmed diagnosis of FH: Guidance on LDL-C target concentrations on statin treatment.
• < 10 years of age: if drug treatment is considered appropriate, aim for a 30–50% reduction in LDL-C from baseline or a level< 3.5mmol/
L.
• ≥10 years: aim for a 50% reduction in LDL-C from baseline or a level< 3.5mmol/L.• ≥14 years: if there are additional co-morbidities (e.g, type 1 diabetes) or a very strong family history of early coronary events in adults in
their 2nd and 3rd decade, assuming compliance to statin therapy, we suggest slowly increasing the statin dose and/or addition of Ezetimibe
10mg daily, aiming towards a target LDL-C concentration of< 2.5mmol/l over the next 3–5 years.
Fig. 3. Clinical management of children and young
people with FH.
In children<10 years of age aim for 3.5mmol/L or
a 30–50% reduction in LDL-C from baseline. In
children and young people> 10 years of age aim for
3.5mmol/L or a 50% reduction in LDL-C from
baseline in the first year. From the age of 14 years, if
there are additional co-morbidities (e.g, type 1 dia-
betes) or a very strong family history of early cor-
onary events in adults in their 2nd and 3rd decade,
slowly increase statin dose and/or addition of
Ezetimibe 10mg daily, aiming towards a target LDL-
C concentration of< 2.5mmol/l over the next 3–5
years. Liver function tests (LFTs) and serum creatine
kinase (CK) should be measured before a statin is
commenced. Thereafter, measure CK if indicated and
LFTs annually. Also refer to Box 1 and 2 for man-
agement guidance.
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Our recommended treatment pathways for children and young
people with paediatric FH are shown in Fig. 3. In Box 1, we give LDL-C
targets that we consider reasonable and achievable, based on previously
published guidelines. These generic guidelines should, however, be
discussed with the family and adjusted according to the individual risk
factors, particularly the family history.
In addition to their established role in diagnosis, the age and sex
specific distributions of LDL-C and TC derived from mutation negative
relatives by Starr et al. [22] provides a graphic illustration of expected
values in the presence or absence of FH-causing mutations, which may
be useful in explaining the range of cholesterol values in affected
compared to unaffected relatives and the goals of lipid lowering treat-
ment. In children, using these charts, the overall aim of treatment
would be to return LDL-C and TC to the “green zone”, as seen in un-
affected age-appropriate individuals. This concept is likely to be readily
understood by parents and young people, as is the argument that adults
who have been in the “red zone” for several years should ideally
achieve the greater LDL-C reductions required to get them into the
lowest part of the “green zone” as shown in Supplement S1.
6. Statement 2: clinical review
a. All children with a confirmed diagnosis of FH should be reviewed at
their initial clinic visit by a paediatric healthcare professional with
expertise in FH in a child friendly environment with advice on
healthy lifestyle.
b. An individualised care plan for follow-up until 8 years of age should
be formulated at the initial meeting. Options include periodic face-to-
face or telephone consultations with the paediatric FH professional.
c. Occasionally it may be appropriate to start a statin before 8 years of age.
d. All children with FH should be reviewed at 8 years of age for a
repeat lipid profile and reinforcement of dietary and healthy life-
style advice.
e. Use of a statin should be considered in children aged 8–10 years
with LDL-C> 4mmol/l and a strong family history of early CHD.
f. In children with FH aged more than 10 years, following discussion
with the parents, consider statin if LDL-C>3.5mmol/l.
g. All children on a statin should be reviewed regularly by a paediatric
FH professional, 3–6 monthly in the first year and thereafter 6 to 12
monthly as appropriate. Reviews could be a combination of face to
face and telephone consultations as appropriate.
h. All significant side effects to statin should be reported using the
yellow card scheme (British National Formulary)
i. It is recommended that children with FH have their diagnosis coded
in primary and secondary health care records.
7. Treatment options
Statin: Regulation of cholesterol via the LDL-receptor pathway fea-
turing receptor-mediated endocytosis is critical to the onset of athero-
sclerosis. Statins lower serum cholesterol by inhibiting hepatic choles-
terol biosynthesis and up-regulation of hepatic LDL receptors, with
increased clearance of LDL-C. The lipophilic statins cross cell membranes
largely by passive diffusion. Hydrophilic statins (Pravastatin and
Rosuvastatin) require activated carrier-mediated transport with organic
anion transporting polypeptide (OATP) 1B1; they are more selective for
hepatic tissues and are the preferred statins for young children less than
10 years of age, whose brain and gonadal tissues are still maturing [29].
Rosuvastatin is licensed for children aged over 6 years; Pravastatin from
8 years, Simvastatin from 5 years and Atorvastatin from 10 years of age
(British National Formulary for Children).
Side effects of statins: The most frequently discussed side effects of
statin therapy in adults are muscle-related complaints. These are rare in
children, possibly because lower doses are used. In 2017, the Cochrane
report on statin safety in paediatric FH reviewed 26 potentially eligible
studies, of which nine were randomized placebo-controlled studies
(1177 participants) [30]. The median time of intervention and follow-
up was 24 weeks (range six weeks to two years). Statins reduce the
mean LDL-C concentration at all time points. Liver function tests (LFTs)
and creatine kinase (CK) levels were similar in the statin treated and
placebo groups at any time point. Although elevations of these values
occurred in some children, the risks of myopathy and clinical adverse
events were very low and similar in both groups. There were no reports
of rhabdomyolysis and in seven studies that reported ALT level, there
were no abnormal results after up to two years of statin treatment.
Other lipid lowering drugs: In some patients, it may not be possible
to achieve the LDL-C targets we recommend with the statin doses licensed
in children. In these patients, we recommend adding Ezetimibe [31]. This
inhibits intestinal cholesterol absorption and has a synergistic effect with
statins. The licensed dose is 10mg daily from 10 years of age. Diarrhoea is
the commonest side effect but it is usually transient. Bile acid sequestrants
(such as Colestipol and Colestyramine) can also lower the LDL-C but they
are unpalatable and therefore unpopular for use in children. Monoclonal
antibodies to PCSK9 (Evolocumab and Alirocumab) are now used in adults
with FH and paediatric trials are in progress but they need to be given by
injection and will seldom be warranted in children.
8. Adherence to treatment
Adherence should be checked if there is a poor response to statins,
particularly during adolescence, before increasing the dose or potency of
the drug. Long term compliance with treatment is unlikely unless pa-
tients understand and believe the benefits; frequent contact can also help
and may be most conveniently done by telephone. Studies in adults with
FH have shown reasonable treatment adherence but, for many chronic
disorders, adherence is poor during adolescence. Good adherence was,
however, reported in the only study specifically considering statins in
adolescents and young adults with FH [32]. A questionnaire was sent to
214 young adult FH patients who had initiated statin therapy at least 10
years previously and replies were received from 205 subjects (95.8%). Of
these, 169 (82.4%) remained on statin treatment and 78.7% (148 out of
188) had taken at least 80% of their lipid-lowering drugs over the pre-
vious month. Side effects were reported by 40 patients (19.5%), mainly
muscle complaints and gastrointestinal symptoms, but only 3 patients
(1.5%) discontinued statin therapy because of side effects. No rhabdo-
myolysis or other serious adverse events were reported.
9. Statement 3: treatment
a. Children and young people aged ≥10 years with LDL-C>3.5mmol/
l should be considered for lipid lowering therapy and commenced
initially on a once daily dose of Atorvastatin 10mg, Pravastatin
20mg or Rosuvastatin 5mg, the doses being titrated up as required
within the licensed range.
b. In children<10 years of age with FH, LDL-C>4mmol/l and a
family history of early CHD, initially consider once daily Pravastatin
10mg or Rosuvastatin 5mg once daily.
c. All children and young people with FH on a statin must be mon-
itored regularly by a paediatric FH professional.
d. All children and young people should have baseline CK and LFTs
measured before commencing a statin and repeated when the dose is
altered. LFTs should be monitored annually. Measure CK if muscle
symptoms are reported.
e. All children with FH on a statin should have regular monitoring of
weight and growth (and puberty if appropriate).
f. The suggested target for children aged less than 10 years is 3.5mmol/
l or a 30–50% reduction in LDL-C concentration from baseline.
g. The recommended target for children and young people aged>10
years is 3.5 mmol/l or a 50% reduction in LDL-C concentration from
baseline in the first 12 months. The addition of Ezetimibe 10mg
daily as an adjunctive therapy to statin should be considered to
achieve target levels of LDL-C concentration as above.
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h. In adolescents from 14 years of age, if there are additional co-
morbidities (eg type 1 diabetes) or a very strong family history of
early coronary events in adults in their 2nd and 3rd decade, as-
suming compliance to statin therapy, we recommend slowly in-
creasing the statin dose and/or addition of Ezetimibe 10mg daily,
aiming towards a target LDL-C concentration of< 2.5mmol/l over
the next 3–5 years (Box 1).
10. Diet and life-style
Tobacco smoking greatly increases the risk of heart disease in
people with FH and the importance of avoiding this should be em-
phasized from the time of diagnosis. Parents should be encouraged to
stop smoking, partly to reduce the risk of their children adopting the
habit. Although e-cigarettes are associated with a much lower risk of
cancer and probably of heart disease, uncertainties remain and they can
lead to nicotine addiction. Life-long avoidance of both smoking and/or
vaping, is strongly recommended.
It is important to ensure that children and young people with FH
have adequate calories, including calories from fats, to support and
maintain growth. The emphasis should always be on healthy eating and
not dietary or calorie restrictions. The dietary guidance for children
with paediatric FH is described in Box 2.
Molven et al. [24] demonstrated that counseling children with FH in
Norway on healthy eating resulted in a long lasting effect, with children
and adolescents choosing foods with an appropriate fatty acid compo-
sition, with less saturated fat.
The Task Force for the Management of Dyslipidaemias of the
European Society of Cardiology (ESC) and European Atherosclerosis
Society (EAS) suggest that based on the level of LDL-C lowering, func-
tional foods with plant sterols/stanols (at least 2 g/day with the main
meal) may be considered in children (>6 years) with FH [24]. The
possible decrease in carotenoid and fat-soluble vitamin levels by sterols/
stanols can be prevented with a balanced diet rich in these nutrients. The
nutritional adequacy of the overall diet should be assessed to ensure all
nutrient requirements for healthy growth are being met.
The cumulative exposure of coronary arteries to the lifelong LDL-C
elevation can be estimated by calculating the LDL-C burden (LDL-C con-
centration x age in years), which can also be used to demonstrate the
potential usefulness of dietary stanol/sterol treatment. Compared to un-
treated FH patients, the LDL-C burden from the age of 10 years was re-
duced by 15% on a statin and by 21% on a statin and dietary plant stanol
[33]. Longer-term studies are required to confirm these positive findings.
11. Statement 4: diet and lifestyle
a. Life-long avoidance of smoking/vaping should be strongly re-
commended.
b. Children with FH should be educated on food groups and healthy
food choices
c. Dietary guidance on age appropriate fat intake should be provided
by a paediatric dietitian and ensure adequate growth. The dietitian
should also monitor intake of plant stanol/sterol as appropriate.
d. Age appropriate activity and energy intake should be encouraged in
all children with FH.
e. The importance of avoiding excessive alcohol should be discussed
when appropriate with adolescents.
12. Adolescence and transition to adult services
Transition describes the process of transferring a child to an adult
model of health care. Adolescents and young adults often consider
healthcare of low importance compared with the other aspects of their
transition to adulthood (e.g. education, employment, relationships) and
they often demonstrate poor engagement with healthcare. It is, therefore,
important to start teaching children with FH about their condition and its
management from 10 to 12 years of age. Better education of young FH
patients should improve long-term adherence [34–38], and HEART UK
have produced information sheets for different aged children [39].
Patients should be offered the opportunity to attend part of the
consultation alone from about 14 years of age, depending on their
wishes and capacity. This provides an opportunity to discuss treatment
plans, lifestyle, pregnancy/contraception issues and medication com-
pliance, before the parents/guardians are invited to join the consulta-
tion for further discussion. When lipid-modifying drug therapy is first
considered, girls should be advised of the potential for adverse effects
on the foetus during pregnancy, and this should be revisited annually.
Girls with FH should be offered a choice of effective contraceptive
methods if appropriate [20] and advised to take folic acid and dis-
continue statins 3 months before a planned conception and throughout
pregnancy and breastfeeding.
Smooth transition to adult services is facilitated if the patient is seen
jointly by the paediatric FH professional and adult lipidologist on a few
occasions prior to transfer. Joint clinics are particularly useful from 14
years of age onwards but throughout childhood family follow-up clinics
for children and adults can enhance the family's quality of life, reducing
travel costs and time off work. They also reinforce the healthy life-style
interventions and dietary habits that apply to all affected individuals
within the family. Family clinics must, however, include a paediatric
FH professional and take place in a child friendly setting.
Individuals or families may be concerned about the implications of a
FH diagnosis for insurance and employment. There is a moratorium from
the Association of the British Pharmaceutical Industry (ABPI) on asking
about predictive genetic tests, but they can ask about confirmed diagnoses.
Although the outcome for a diagnosed child/young person is excellent, the
concept of lifetime exposure (or lack of exposure) to elevated LDL-C is
generally not well understood by employers or insurance companies.
Patients may find that their condition is not completely understood out-
side the clinical arena, and may need further advice from their own
clinician or an appropriate representative body, such as HEART UK.
In the Netherlands, an agreement between insurers and other par-
ties in society to avoid genetic discrimination has been established to
improve access to insurances for pre-symptomatic subjects with genetic
FH. In 2003 insurers agreed to underwrite FH according to a set of
specific guidelines. These guidelines stipulate that subjects with genetic
FH and free of cardiovascular disease should be offered an uncondi-
tional life insurance policy under most conditions. The main require-
ments were that individuals had LDL-cholesterol levels, either treated
or untreated, at or below 4.0mmol/l although other cardiovascular risk
factors, such as smoking, hypertension, diabetes or obesity, had to be
absent at the time of life insurance application [40].
In 2012, Huijgen et al. [41] tested the effectiveness of the 2003 im-
plementation of life insurance guidelines for FH in The Netherlands. A
total of 2825 subjects that had participated in the genetic testing for FH
between 1998 and 2003 were included in a survey. Comparisons of
Box 2
Lifestyle advice: Adapted from [18], [21].
Diet: Total fat intake is 30% or less of total energy intake; saturated fats are 10% or less of total energy intake; intake of dietary cholesterol less
than 300mg/day; saturated fats to be replaced by increasing the intake of monounsaturated and polyunsaturated fats.
Physical exercise: Age appropriate activity and energy intake to achieve and maintain a healthy body weight.
Smoking: Total avoidance of smoking/vaping should be strongly recommended.
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unconditional acceptance rates before and after FH diagnosis and before
and after the guidelines were analysed. The percentage of applicants
without FH obtaining insurance on normal terms was 98.6%, which was
significantly greater than for applicants with genetic FH. However, the
vast majority (86.3%) of FH patients had been accepted for life insurance
and this percentage was significantly higher when compared to data
before implementation of these guidelines. The authors conclude that
their results cautiously suggest that access to life insurance for in-
dividuals with genetic FH improved in The Netherlands following the
introduction of guidelines for insurers. Unconditional acceptance for life
insurance for FH in the Netherlands has significantly improved when
compared to a decade ago. The authors conclude that an agreement
between insurers and other parties in society to avoid genetic dis-
crimination has proven a viable strategy to improve access to insurance
for pre-symptomatic subjects with genetic FH in The Netherlands. They
suggest that this approach could encourage health care workers in other
countries to reach similar settlements with insurance companies.
13. Statement 5: adolescence and transition to adult services
a. Children with FH should be taught about their condition and its
management from 10 to 12 years of age.
b. Family clinics for FH are encouraged but should always include a
paediatric FH professional and take place in a child friendly setting.
c. From about 14 years of age onwards, adolescents should be seen
partly on their own if they wish and joint clinics with an adult li-
pidologist should be considered.
d. Adherence to statins should be monitored (using medication ad-
herence reporting scales)
e. The importance of diet, healthy lifestyle measures and avoidance of
smoking/vaping should be stressed and girls on statin therapy
should be given advice on contraception if appropriate.
f. Children with FH should be transferred to an adult lipid clinic at
16–18 years of age.
14. The UK FH Children's register
Following the 2010 UK National Audit of FH services, the UK pae-
diatric FH register was developed specifically to collate information on
children with FH and to monitor the safety of statin use in paediatric FH.
The register has ~70 clinicians entering routine clinical care data an-
nually. The register currently has over 600 children registered and 880
annual follow up data. In 300 children (51% boys, 75% Caucasian), the
untreated mean (SD) LDL-C was 5.50(1.49) mmol/L. As expected, the
proportion of children on statins varied significantly (p < 0.005) by age
group (<5 years=0%, 5–10 years=16.7%, 10–15years=57.1%,>
15years=73.2%). Those subsequently on statin treatment had sig-
nificantly higher LDL-C concentrations at diagnosis than the overall
group (6.01(1.46) mmol/L v 5.31(1.37) mmol/L, p=0.00007), and a
higher proportion had a family history of early CHD in a parent or first
degree relative (28.4% v 19.0%, p=0.09). Overall, statin treatment
reduced LDL-C by 31%, and no child showed elevated levels of markers
of liver toxicity or muscle damage [42]. The data indicate that treatment
decisions in children with FH are being appropriately based on a stronger
family history of CHD and the LDL-C concentration.
The annual follow up data has allowed the register to monitor
growth rates in those taking or not taking statins. There were no dif-
ferences in annual growth rate in statin vs no-statin groups. The long-
term continuation of the register activities, including monitoring into
adulthood, will help to reassure clinicians and parents about the safety
and efficacy of statin therapy. All children and young people with FH
should be invited to join the Registry.
15. Potential future universal screening for FH
Unfortunately, except in the Netherlands, current cascade screening
programs have failed to identify most FH patients in the community,
primarily because relatively few index cases are identified [1]. A
pathway for identification of children with FH using universal Child-
Parent Screening was proposed and tested by Wald et al. [43]. In this
study of 10,095 children at 92 UK general practices, the authors de-
monstrated that screening children for FH was feasible and acceptable at
the time of routine immunization between 1 and 2 years of age (median
age 13 months), when a cholesterol measurement is most discriminatory
for identifying individuals with FH. The results showed that screening
10,000 children identified 40 children with FH, with a total cholesterol
≥1.35 Multiples of the Median or MoM (95th centile) and an FH mu-
tation and 8 with two total cholesterol measurements>1.50MoM (99th
centile) without an FH mutation. For every child who had mutation
positive FH, a parent with the same mutation was also identified. In the
study all parents were offered statin treatment immediately and dietary
advice was offered to both parent and child with a recommendation to
consider a statin in the child from age 8 years. In a subsequent, paper, the
Child-parent screening approach was combined with cascade testing
(Child-parent Cascade Screening), based on two new per known FH cases
identified, with results showing that an integrated strategy would iden-
tify 1 new individual with FH for every 70 children screened, at a cost of
about £5 per child screened and £960 per new FH case identified [44].
The cost effectiveness of such an approach has been modeled, in-
cluding the cost for monitoring and treating the children and adults
identified and suggests a cost per Quality Adjusted Life Year Gained of
£12,480 [45], which is well under the NICE threshold for an intervention
to be recommended. The UK National Screening Committee is currently
considering the feasibility and acceptability of this approach, and if ap-
proved we anticipate that children identified in this way should enter the
care pathway as shown in Fig. 3 and be managed as described above.
16. Conclusions
This consensus statement builds on previous guidelines [19,20] and
provides a comprehensive care pathway for children and young people
with heterozygous FH. Statins have been used in adults with heterozygous
FH and in those in the general population since the late 1980s [2–4], and
in the ensuing 40 years no major long term safety issues have been
identified. Children and young people with heterozygous FH seldom
present with overt clinical features of disease. However, early onset
atherosclerosis has been documented by CIMT studies in children with FH
[16], and prevention of progression of CIMT can be achieved with statin
treatment [17]. Studies in children have also found no long-term safety
concerns, and the 2017 Cochrane review concluded that statin use in
childhood was safe in the medium term [30]. This finding is fully sup-
ported by the UK FH Children's Register which found no instances of
safety issues and an equal growth rate in statin treated and non-treated
children [26]. However, longitudinal studies are lacking and will be
helpful to confirm the long-term safety of statins started in children.
We believe that this is the first consensus statement that addresses
the follow up of children identified on cascade testing, those identified
whilst measuring lipid profiles incidentally, and if universal child-
parent screening is made available. This consensus statement also
provides defined guidance on the initiation of statin and target goals for
LDL-C on a statin for children and young people with heterozygous FH.
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